Caliway Biopharmaceuticals Co (TPE:6919) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Caliway Biopharmaceuticals Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Caliway Biopharmaceuticals Co's long-term debt to total assets ratio declined from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Caliway Biopharmaceuticals Co is progressively becoming less dependent on debt to grow their business.

Caliway Biopharmaceuticals Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co LT-Debt-to-Total-Asset Chart

Caliway Biopharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.51

0.04

0.02

Caliway Biopharmaceuticals Co Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial								-	-	-	-	-

Caliway Biopharmaceuticals Co LT-Debt-to-Total-Asset Calculation

Caliway Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	2.998	/	9770.507
	=	0.00

Caliway Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	2.998	/	9770.507
	=	0.00

Caliway Biopharmaceuticals Co (TPE:6919) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Caliway Biopharmaceuticals Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Caliway Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (TPE:6919) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.99, Sec. 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221

Website

https://www.caliway.com.tw

Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its pipeline candidate is, CBL-514, CBA-539, and CBO-012.

Caliway Biopharmaceuticals Co Headlines

No Headlines